Table 1 Patient characteristics
Characteristic | Number (%) |
|---|---|
n = 20 | |
Age (years) | |
Median | 72 |
Range | 50–79 |
Gender | |
Male | 13 (65) |
ECOG performance status | |
0 | 8 (40) |
1 | 10 50) |
2 | 2 (10) |
Histology | |
Adenocarcinoma | 13 (65) |
Squamous and other | 7 (35) |
EGFR mutation / ALK rearrangement | 4 (20) / 1 (5) |
First-line chemotherapy | |
Platinum-based doublet | 16 (80) |
Targeted agents | 4 (20) |
Support Team Assessment Schedule scores | |
Cough (more than 1) | 11 (55) |
Dyspnea (more than 1) | 2 (10) |
Pain (1) | 7 (35) |
Fatigue (more than 1) | 4 (20) |
Sleep disturbance (more than 1) | 4 (20) |
Patients’ anxiety (1) | 20 (100) |
Patients’ insight of advanced disease (0) | 3 (15) |